TY - JOUR T1 - Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in Spondyloarthritis except for Psoriatic Arthritis JO - Reumatología Clínica (English Edition) T2 - AU - Juanola Roura,Xavier AU - Zarco Montejo,Pedro AU - Sanz Sanz,Jesús AU - Muñoz Fernández,Santiago AU - Mulero Mendoza,Juan AU - Linares Ferrando,Luis Francisco AU - Gratacós Masmitja,Jordi AU - de Vicuña,Rosario García AU - Fernandez Carballido,Cristina AU - Collantes Estevez,Eduardo AU - Batlle Gualda,Enrique AU - Ariza Ariza,Rafael AU - Loza Santamaría,Estíbaliz SN - 21735743 M3 - 10.1016/S2173-5743(11)70022-3 DO - 10.1016/S2173-5743(11)70022-3 UR - https://www.reumatologiaclinica.org/en-consensus-statement-spanish-society-rheumatology-articulo-S2173574311700223 AB - ObjectiveDue to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT. MethodsRecommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. ResultsWe have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. ConclusionsWe present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA. ER -